The French drug maker Sanofi said on Friday that it had secured an agreement of up to $2.1 billion to supply the U.S. federal government with 100 million doses of its experimental coronavirus vaccine, the largest such deal announced to date.
The arrangement brings the Trump administration’s investment in coronavirus vaccine projects to more than $8 billion. This sprawling, multiagency effort, known as Operation Warp Speed, is placing bets on multiple vaccines and is paying companies to manufacture millions of doses before clinical trials have been completed.
“The global need for a vaccine to help prevent Covid-19 is massive, and no single vaccine or company will be able to meet the global demand alone,” Thomas Triomphe, executive vice president and global head of Sanofi Pasteur, the company’s vaccine division, said in a statement.
Also on Friday, the European Union said it was working on a deal with Sanofi to buy up to 300 million doses of potential vaccines to distribute to citizens in its 27 member countries. The announcements came two days after a deal with the British government to supply up to 60 million doses of the vaccine. Financial details of those deals were not disclosed.
Under the U.S. deal, Sanofi and its partner, the British pharmaceutical company GlaxoSmithKline, will receive federal funding to pay for clinical trials as well as for manufacturing the vaccine. Sanofi said the deal also includes an option for the company to supply an additional 500 million doses. The company expects to begin clinical trials to test for safety in September, followed by late-stage efficacy trials before the end of this year. Sanofi said it could apply for regulatory approval in the first half of next year.
If the vaccine is successful, it would be made available to Americans at no cost, other than what providers charge to administer it, the federal government said in a statement.
The head of Operation Warp Speed, Moncef Slaoui, is a former GSK executive who as of May held just under $10 million in GSK stock. Dr. Slaoui’s financial ties to some of the companies that are pursuing coronavirus vaccines have raised questions about conflicts of interest.
Dr. Slaoui is not a federal employee, instead working under a $1 contract that exempts him from federal rules that would require him to list his outside positions, stock holdings and other potential conflicts. Dr. Slaoui said in an interview in May that he was determined to avoid any conflicts of interest, but that his GSK stock represented his retirement from 29 years at the company, and that he had told federal officials he would not take the job if he had to sell it.
Sanofi and GSK did not say how much of the federal money would go to each company — only that Sanofi would receive the most. GSK did not comment on whether Dr. Slaoui had recused himself from negotiations over the deal. A senior administration official said all agreements were negotiated by federal “acquisition professionals” and that Dr. Slaoui did not play a role in the negotiations.
A handful of other vaccine candidates are already in late-stage clinical trials and some, such as AstraZeneca and Moderna, have said a vaccine could be ready before the end of this year.
The Coronavirus Outbreak ›
Frequently Asked Questions
Updated July 27, 2020
Should I refinance my mortgage?
- It could be a good idea, because mortgage rates have never been lower. Refinancing requests have pushed mortgage applications to some of the highest levels since 2008, so be prepared to get in line. But defaults are also up, so if you’re thinking about buying a home, be aware that some lenders have tightened their standards.
What is school going to look like in September?
- It is unlikely that many schools will return to a normal schedule this fall, requiring the grind of online learning, makeshift child care and stunted workdays to continue. California’s two largest public school districts — Los Angeles and San Diego — said on July 13, that instruction will be remote-only in the fall, citing concerns that surging coronavirus infections in their areas pose too dire a risk for students and teachers. Together, the two districts enroll some 825,000 students. They are the largest in the country so far to abandon plans for even a partial physical return to classrooms when they reopen in August. For other districts, the solution won’t be an all-or-nothing approach. Many systems, including the nation’s largest, New York City, are devising hybrid plans that involve spending some days in classrooms and other days online. There’s no national policy on this yet, so check with your municipal school system regularly to see what is happening in your community.
Is the coronavirus airborne?
- The coronavirus can stay aloft for hours in tiny droplets in stagnant air, infecting people as they inhale, mounting scientific evidence suggests. This risk is highest in crowded indoor spaces with poor ventilation, and may help explain super-spreading events reported in meatpacking plants, churches and restaurants. It’s unclear how often the virus is spread via these tiny droplets, or aerosols, compared with larger droplets that are expelled when a sick person coughs or sneezes, or transmitted through contact with contaminated surfaces, said Linsey Marr, an aerosol expert at Virginia Tech. Aerosols are released even when a person without symptoms exhales, talks or sings, according to Dr. Marr and more than 200 other experts, who have outlined the evidence in an open letter to the World Health Organization.
What are the symptoms of coronavirus?
Does asymptomatic transmission of Covid-19 happen?
- So far, the evidence seems to show it does. A widely cited paper published in April suggests that people are most infectious about two days before the onset of coronavirus symptoms and estimated that 44 percent of new infections were a result of transmission from people who were not yet showing symptoms. Recently, a top expert at the World Health Organization stated that transmission of the coronavirus by people who did not have symptoms was “very rare,” but she later walked back that statement.
Sanofi’s coronavirus vaccine relies on a protein-based technology that the company already uses to produce an influenza vaccine. It is similar to a technique used by another company, Novavax, that will receive up to $1.6 billion from the Defense Department and the Department of Health and Human Services to develop its experimental vaccine. GSK is supplying the Sanofi vaccine with an adjuvant, an ingredient used in many vaccines that boosts the immune response.
Sanofi is also developing a separate vaccine in partnership with Translate Bio that uses so-called messenger RNA to provoke an immune response in the body. That vaccine is expected to enter clinical trials in the fall.
As a French company, Sanofi has had to carefully navigate the geopolitics of vaccine development. In May, the company’s chief executive, Paul Hudson, faced backlash after he said the United States would get the largest number of doses because they were investing the most.
The remarks caused the company to backpedal, explaining that “We have always been committed in these unprecedented circumstances to make our vaccine accessible to everyone.”
Matina Stevis-Gridneff contributed reporting from Brussels.
